Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted piperazine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and other psychotic disorders.
Type:
Grant
Filed:
March 30, 2001
Date of Patent:
February 8, 2005
Assignee:
Merck Sharp & Dohme Ltd
Inventors:
Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher